Dual Role of Neuroplastin in Pancreatic β Cells: Regulating Insulin Secretion and Promoting Islet Inflammation

Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an endoplasmic reticulum (ER)-resident secretory protein that reduces inflammation and promotes proliferation in pancreatic β cells. Numerous studies have highlighted the potential of MANF as a therapeutic agent for diabetes mellitus (DM), making it essential to understand the mechanisms underlying MANF’s functions. In our previous search for a molecule that mediates MANF signaling, we identified Neuroplastin (NPTN) as a binding partner of MANF that localizes on the cell surface. However, the roles of NPTN in pancreatic β cells remain unclear. In this study, we generated β cell-specific Nptn knockout (KO) mice and conducted metabolic characterization. NPTN deficiency improved glucose tolerance by increasing insulin secretion and β cell mass in the pancreas. Moreover, proliferation and mitochondrial numbers in β cells increased in Nptn KO islets. These phenotypes resulted from elevated cytosolic Ca2+ levels and subsequent activation of downstream molecules. Simultaneously, we demonstrated that NPTN induces the expression of proinflammatory cytokines via the TRAF6-NF-κB axis in β cells. Additionally, NPTN deficiency conferred resistance to STZ-induced diabetic phenotypes. Finally, exogenous MANF treatment in islets or β cells led to similar phenotypes as those observed in NPTN-deficient models. These results indicate that NPTN plays important roles in the regulation of insulin secretion, proliferation, and mitochondrial quantity, as well as pro-inflammatory responses, which are antagonized by MANF treatment. Thus, targeting the MANF-NPTN interaction may lead to a novel treatment for improving β cell functions in diabetes mellitus. Significance statement Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an endoplasmic reticulum (ER)-resident small secretory protein that has the potential as therapeutic agent for various diseases related to inflammation and ER stress, such as Type 1 diabetes mellitus. Our work shed light on the roles of a binding partner protein of MANF, Neuroplastin (NPTN), in pancreatic β cells. We demonstrated NPTN regulates Ca2+ dynamics as well as inflammation in pancreatic β cells. NPTN deficiency caused improved insulin secretion as well as the resistance to Type 1 diabetic phenotypes. We also found out that MANF treatment leads to similar phenotypes observed in NPTN deficient models through antagonizing NPTN’s functions. Overall, our results provide a new insight into treatment for improving β cell functions in diabetes mellitus. ### Competing Interest Statement FU is an inventor of three patents related to the treatment of Wolfram syndrome, US 9,891,231 SOLUBLE MANF IN PANCREATIC BETA CELL DISORDERS and US 10,441,574 and US 10,695,324 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ER STRESS DISORDERS. FU is a Founder and President of CURE4WOLFRAM, INC, and a Chair of the Scientific Advisory Board for Opris Biotechnologies, INC.